Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
Hepatocellular Carcinoma
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Soft Tissue Sarcoma

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

ASH CLL Spotlight

A spotlight on chronic lymphocytic leukemia (CLL) from the 2016 ASH Annual Meeting at the San Diego Convention Center in San Diego, California, from December 3 to December 6, 2016.
High Response Rate With Venetoclax in Relapsed/Refractory CLL
High Response Rate With Venetoclax in Relapsed/Refractory CLL
An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation
An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation
Nitin Jain, MD
Induction of Ibrutinib Regimen Achieves 100% Response Rate in CLL
Induction of Ibrutinib Regimen Achieves 100% Response Rate in CLL
Jason M. Broderick
Lenalidomide Maintenance Substantially Improved PFS in High-Risk Subgroup of CLL
Lenalidomide Maintenance Substantially Improved PFS in High-Risk Subgroup of CLL
Wayne Kuznar
Ibrutinib Shows Impressive 5-Year Results in CLL/SLL
Ibrutinib Shows Impressive 5-Year Results in CLL/SLL
Lauren M. Green
Nivolumab/Ibrutinib Combo Shows Encouraging Activity for Richter Transformation
Nivolumab/Ibrutinib Combo Shows Encouraging Activity for Richter Transformation
Silas Inman
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.